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The purpose of this study was to evaluate a methodology to reduce scatter and
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leakage radiations to patients’ surface and shallow depths during conventional and
were placed on top of a stack of solid water phantoms, and the bolus effect on surface and shallow depth doses for both open and intensity-modulated radiotherapy
(IMRT) beams was evaluated using thermoluminescent dosimeters and ion chamber
measurements. Contralateral breast dose reduction caused by the bolus was evaluated by delivering clinical postmastectomy radiotherapy (PMRT) plans to an anthropomorphic phantom. For the solid water phantom measurements, surface dose
reduction caused by the Superﬂab bolus was achieved only in out-of-ﬁeld area and
on the incident side of the beam, and the dose reduction increased with bolus thickness. The dose reduction caused by the bolus was more signiﬁcant at closer distances from the beam. Most of the dose reductions occurred in the ﬁrst 2-cm depth
and stopped at 4-cm depth. For clinical PMRT treatment plans, surface dose reductions using a 1-cm Superﬂab bolus were up to 31% and 62% for volumetric-modulated arc therapy and 4-ﬁeld IMRT, respectively, but there was no dose reduction
for Tomotherapy. A Superﬂab bolus can be used to reduce surface and shallow
depth doses during external beam radiotherapy when it is placed out of the beam
and on the incident side of the beam. Although we only validated this dose reduction strategy for PMRT treatments, it is applicable to any external beam radiotherapy and can potentially reduce patients’ risk of developing radiation-induced side
effects.
PACS

87.53.Bn, 87.53.Jw, 87.53.Kn, 87.55. DKEY WORDS

external beam radiotherapy, patient safety, shallow depth dose, shielding, Superﬂab bolus,
surface dose

---------------------------------------------------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
J Appl Clin Med Phys 2018; 19:2:137–143

wileyonlinelibrary.com/journal/jacmp

|

137

138

|

YOON

1 | INTRODUCTION

ET AL.

tested; and dose reductions for advanced radiotherapy techniques in
clinically realistic situations were also evaluated.

The number of cancer survivors has been increasing. It is estimated
that cancer survivors will account for about 5.4% of the US population in 2024, and approximately half of all cancer patients receive
radiotherapy as a part of their treatments (www.cancer.gov). There
is a growing concern about patient safety because side effects

2 | MATERIALS AND METHODS
2.A | Surface dose evaluation

induced by cancer treatments may remain and seriously affect their

A stack of solid water phantoms was used to evaluate the skin dose

quality of life for many of these survivors. While the goal of radio-

with and without a Superﬂab bolus (Radiation Products Design Inc.,

therapy is to deliver a highly conformal dose to the tumor area only,

Albertville, MN, USA) placed in the ﬁeld or out of the ﬁeld (Fig. 1). The

normal tissues outside the target also receive radiation doses includ-

Superﬂab boluses used in this study are commercial products and

ing medium to high dose adjacent to the target, scatter and leakage

made of synthetic gel which is water equivalent. They have the same

doses from the treatment machine, and scatter dose within the

size (30 9 30 cm2) but the thickness varies. The bolus can be cut to

patient. These normal tissue doses can cause a spectrum of acute

any shape to ﬁt the patient’s contour for any radiotherapy when nec-

and chronic radiogenic side effects for the patients.1–14 Epidemio-

essary, although we did not cut them in this study. Thermolumines-

logic studies indicate the majority of second cancers occurred in the

cent dosimeters (TLDs) were placed at the measurement points

low- or intermediate-dose areas,15,16 and current data support lin-

shown in Fig. 1. Measurement points 1 and 2 were on the beam axis

ear-no-threshold dose-risk model indicating a ﬁnite risk of develop-

and in the ﬁeld, and points 3 and 4 were 10 cm away from the beam

ing second cancer even for the lowest radiation dose.17,18 The

axis and out of the ﬁeld. For in-ﬁeld measurements, 6 and 10 MV

advanced radiotherapy techniques like intensity-modulated radio-

open beams with 10 9 10 cm2 ﬁeld size at the isocenter and IMRT

therapy (IMRT) will increase the low-dose volume because of beam

beams with a maximum multileaf collimator (MLC) opening less than

modulations and can increase the risk of developing second

10 9 10 cm2 at the isocenter were used, and 100 monitor units

19,20

cancers.

(MUs) were delivered using Elekta Inﬁnity linac (Elekta Corporation,

Over the years, people have been trying to reduce normal tissue

Stockholm, Sweden). The source-to-surface (SSD) was 90 cm and the

doses during radiotherapy, and external shielding is one of the effec-

beam isocenter was located at 10 cm depth and 10 cm away from the

tive approaches to reduce the scatter and leakage doses from the

edge of the phantom (Fig. 1), and only 1-cm Superﬂab bolus was used

treatment machine. Multiple studies21–24 reported lead blocks can be

in the in-ﬁeld measurements and was placed above point 1 or 2. For

used to limit fetal dose during radiotherapy for pregnant patients;

out-of-ﬁeld measurements, the same open photon beam with

lead sheets had also been shown to reduce scatter radiation to the
contralateral breast or heart during breast cancer radiotherapy.25–29
Most of the previous studies chose a high-density metal as the
shielding material, and holders usually had to be used to support the

15 cm

heavy shielding blocks, which makes the procedure expensive, trou-

10 cm
m

blesome, and time consuming. Occasionally, the shielding block may

7 cm

be dropped by accident and could hurt the patient or staff. Although
some specially designed shielding device made of a very thin lead

Incident side

sheet can overcome some of these problems, it has the limited avail-

3

1

ability, does not match the body surface, and additional material has

Beam axis

to be used to ﬁll the gap between the body and the shielding device
30

to reduce the lateral scattering dose.

One study reported that plac-

ing a Superﬂab bolus on the surface of the contralateral breast dur-

Solid water

ing external radiotherapy could reduce the surface dose under the
bolus.31 This is an attractive alternative because the Superﬂab bolus
is widely available, has a much lower cost compared with lead
sheets, and can be put directly on the patient and conform to the
body shape very well. The effect of the bolus was only evaluated for

Exit side

4

2
Radiation beam

the conventional tangential breast radiotherapy in that study and
only 1-cm Superﬂab bolus was used.31
In this study, we investigated this bolus effect in more details:
the bolus was placed in the ﬁeld and out of the ﬁeld, on the incident
and exit sides of the radiation beam; various bolus thicknesses were
used; both surface and shallow depth doses at different distances
from beam axis were investigated; both static and IMRT beams were

F I G . 1 . A solid water phantom used for bolus effect evaluation.
Surface points 1 and 2 were on the beam axis and in the ﬁeld, and
points 3 and 4 were 10 cm away from the beam axis and out of the
ﬁeld. For the radiation beam shown in the ﬁgure, points 1 and 3
were on the incident side, and points 2 and 4 were on the exit side
of the beam. We also measured doses 7, 10, and 15 cm away from
the beam axis and at various depths.
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F I G . 2 . An Atom phantom (CIRS) with a
breast attachment. Surface doses were
measured on the contralateral breast
attachment (points 1–5 in the left ﬁgure).
A Superﬂab bolus was placed on the
ipsilateral side to improve skin coverage.
Another 1-cm Superﬂab bolus was placed
on the contralateral breast during radiation
delivery to reduce surface dose but was
not shown here for visual clarity.
2000 MUs and IMRT beam with 1982 MUs were delivered to accumulate enough TLD readings. Boluses of 0.5, 1, 1.5, and 2 cm thick-

2.C | Bolus effect on breast cancer radiotherapy

nesses were used in the out-of-ﬁeld measurements because we are

To test the bolus effect in clinically realistic situations, we used an

more interested in dose reductions, and the bolus was placed out of

Atom dosimetry phantom (CIRS, Inc., Norfolk, VA, USA) for treatment

the beam with its edge aligned with the ﬁeld edge.

planning and dose measurements (Fig. 2). The phantom was scanned

Each TLD dosimeter contained approximately 45 mg TLD-100

by a GE LightSpeed 16 Slice computed tomography (CT) scanner (GE

(LiF:Mg,Ti) powder sealed in a cellophane packet with a volume of

Healthcare, Little Chalfont, United Kingdom), and CT images with

approximately 1 9 1 9 0.2 cm . After TLD measurements, we per-

2.5 mm slice thickness were imported into the Pinnacle 9.8 treatment

formed TLD calibrations by placing TLD packets in solid water phan-

planning system (TPS) (Philips Healthcare, Amsterdam, Netherlands)

toms, delivering a known dose to the TLD packet using the radiation

for treatment planning. Planning target volume (PTV) and organs at

beam of a speciﬁed energy, and recording the TLD readings. This

risk (OARs) were contoured in the TPS and were approved by a physi-

was repeated for several dose levels and a calibration curve was cre-

cian. Postmastectomy radiotherapy (PMRT) plans were generated

3

ated based on the readings. The TLD packets were read using a

including volumetric-modulated arc therapy (VMAT), 4-ﬁeld IMRT,

REXON UL-320 Reader (Rexon Components, Inc., Beachwood, OH,

and Tomotherapy, with the prescription dose of 50 Gy in 25 fractions.

USA). The TLD powder in each packet was divided into three sam-

For VMAT plan, dual-arc with 230° rotations (between 180° and

ples of approximately 15 mg each, and the three samples were used

310°) was used to cover the whole PTV. For 4-ﬁeld IMRT plan, three

to determine the mean dose and standard deviation (SD) of the

6 MV IMRT beams with gantry angles of 295°, 315°, and 150°, and

mean for each TLD packet. The uncertainty of the dose measured

one 10 MV IMRT beam with gantry angle of 170° were used to cover

by each TLD is ≤4% according to the literature.32,33

the whole PTV. For Tomotherapy, CT images and contoured structures were exported from Pinnacle into TomoTherapyâ Hi∙Art TPS
(Accuray, Madison, WI, USA), and a pitch of 0.287, a modulation factor

2.B | Impact of distance and depth on the bolus
effect
To further evaluate the impact of distance and depth on dose reductions caused by the Superﬂab bolus, we measured doses 7, 10, and
15 cm away from the beam axis, at various depths and on the incident side, using the setup in Fig. 1 with and without Superﬂab
boluses of various thicknesses placed on the phantom surface and

of 2.8, 5.02 cm ﬁeld width and ﬁne dose grid were used for
Tomotherapy optimization. For all treatment techniques, a 1-cm
Superﬂab bolus was placed on the ipsilateral breast to improve skin
coverage. TLDs were placed at the measurement points to evaluate
the surface dose reduction on the contralateral side, as shown in
Fig. 2. The measurements were performed with and without placing a
1-cm Superﬂab bolus on the contralateral breast attachment.

out of the beam. A PTW Farmer-type ion chamber (IC) (N30013
PTW Farmerâ Ionization Chamber, PTW, Freiburg, Germany) was

3 | RESULTS AND DISCUSSION

used, and both 6 and 10 MV open (1000 MUs) and IMRT beams
(900 MUs) (the same beams used in Section 2.A except the number

The effects of Superﬂab bolus on surface dose are shown in Table 1.

of MUs) were tested.

It is found that surface dose was reduced only when the point of
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F I G . 3 . Out-of-ﬁeld dose values at various off-axis distances and depths with and without Superﬂab bolus of various thicknesses placed on
top of the solid water phantom for: (a) 6 MV open ﬁeld; (b) 10 MV open ﬁeld; (c) 6 MV IMRT ﬁeld; (d) 10 MV IMRT ﬁeld. The measurement
setup is shown in Fig. 1.
interest is out of the beam and on the incident side of the beam

Surface dose reductions in Table 1 are more signiﬁcant for the

(point 3 in Fig. 1 and Table 1), and the dose reduction increased

open beam because the dose delivered to the calculation point was

with bolus thickness for both open and IMRT beams and for both

much higher from 2000 MUs open beam than from 1982 MUs IMRT

beam energies. This is because the bolus placed on the surface

beam. We scaled the number of MUs of 6 MV IMRT beam from

absorbed the low energy head scatter and leakage photons and the

1982 MUs to 12413 MUs to match the dose from the open beam at

thicker bolus absorbed more.

the calculation point, i.e., to make them deliver the same amount of

Doses increased at the other points: dose increment at point 1

dose to the target like in the clinical radiotherapy, the doses at point 3

(in-ﬁeld and on the incident side) was because the bolus moved the

were 195.4  5.9 cGy without bolus, 123.6  2.9 cGy with 1-cm

surface dose closer to the maximum dose point; dose increments at

bolus, and 103.2  4.8 cGy with 2-cm bolus on top (Table 2). As

point 2 (in-ﬁeld and on the exit side) and point 4 (out-of-ﬁeld and

expected, the absolute dose reductions at the surface are more signiﬁ-

on the exit side) were due to the backscattering photons from the

cant for the scaled IMRT beam because IMRT increases head scatter

bolus and the backscatter increased with bolus thickness. However,

and leakage radiations. However, the relative dose reductions are still

the dose increments on the exit side (points 2 and 4) were relatively

more signiﬁcant for the open beam, which can be explained by the

small compared with the dose reduction on the incident side (point

fact the linac jaws blocked more high energy photons than MLCs,

3). Therefore, for a treatment plan with multiple beam angles, the

while the Superﬂab bolus may not be able to completely absorb those

overall surface dose variation caused by the Superﬂab bolus would

high energy photons. Because this kind of delivery is very time con-

be determined by the beam angles from which the dose contribu-

suming, we did not scale the 10 MV IMRT beam and did not measure

tions are dominant.

at more locations with more bolus thicknesses.
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T A B L E 1 Measured surface doses (mean  SD of the mean) when Superﬂab boluses of various thicknesses were placed on a solid water
phantom, and 6, 10 MV open (2000 MUs), and IMRT (1982 MUs) photon beams were delivered to the phantom. The setup and measurement
point locations are shown in Fig. 1.
Dose (cGy)
Radiation beam

Point

6 MV open

1

6 MV IMRT

10 MV open

10 MV IMRT

No
Bolus

0.5 cm
Bolus

1 cm
Bolus

51.5  0.8

1.5 cm
Bolus

2 cm
Bolus

33.5  0.5

24.7  1.3

23.8  0.4

42.2  0.7

44.5  0.8

44.6  0.7

20.1  0.7

17.7  1.2

16.8  1.1

18.5  0.8

19.6  0.4

20.3  0.9

139.3  2.9

2

56.0  3.2

3

68.4  1.5

49.8  1.1

63.6  3.2

4

39.0  0.3

41.0  1.1

1

30.0  0.8

68.4  2.4

2

31.0  3.4

3

28.9  1.0

23.4  0.4

40.0  4.0

4

17.6  0.4

18.4  0.5

1

51.0  3.5

131.5  2.8

2

63.1  2.5

65.3  3.4

3

77.8  1.4

60.4  1.3

40.5  1.4

28.0  0.9

24.2  0.1

4

36.7  1.0

36.9  1.6

38.4  0.4

39.5  1.8

39.5  0.2

1

35.2  2.4

75.8  2.0

2

35.0  0.9

59.3  3.4

3

35.5  0.9

32.7  1.9

31.9  0.9

24.6  0.7

20.9  0.2

4

10.4  0.2

11.8  0.2

11.9  0.2

15.0  1.9

16.5  0.1

T A B L E 2 Measured surface doses (mean  SD of the mean) when Superﬂab boluses of various thicknesses were placed on a solid water
phantom, and 6 MV open (2000 MUs) and IMRT (12413 MUs) photon beams were delivered to the phantom. The setup and measurement
point locations are shown in Fig. 1. The “no bolus” was used as the reference for dose difference calculations.

Radiation beam

Point

No bolus
Dose (cGy)

1-cm bolus
Dose (cGy)

2-cm bolus

Difference (%)

Dose (cGy)

Difference (%)

6 MV open

3

68.4  1.5

33.5  0.5

51.0

23.8  0.4

65.2

6 MV IMRT

3

195.4  5.9

123.6  2.9

36.7

103.2  4.8

47.2

The effects of Superﬂab bolus on shallow depth dose are shown

reduction was greater than dose increment. For 4-ﬁeld IMRT plan,

in Fig. 3. In out-of-ﬁeld region and on the incident side, for both

the dose reductions were greater than those in VMAT plan and the

open and IMRT ﬁelds, the dose reductions in shallow depths caused

reductions were between 53% and 62%. However, the dose at point

by the bolus were more signiﬁcant at closer distances from the radi-

1 increased because it was in the path of 295° beam and therefore

ation beam (Fig. 3). Most of the dose reductions occurred in the ﬁrst

the dose increased signiﬁcantly. For the other points, the bolus

2-cm depth and the dose reductions stopped at 4-cm depth in all

reduced skin dose signiﬁcantly because the contralateral breast was

cases. These show that a Superﬂab bolus could effectively absorb

not included in the beam path or on any beam’s exit side. Because

scatter and leakage radiations and could reduce not only the surface

Tomotherapy is characterized by full-arc beams, any point on the

dose but also shallow depth doses for both open and IMRT ﬁelds.

surface will always be on both incident and exit sides of the beams

When the Superﬂab bolus was used for clinical PMRT beams,

and the beneﬁt of using the bolus is diminished.

surface doses were reduced in most cases except Tomotherapy, as

Reduction of undesirable doses from radiotherapy treatments

shown in Table 3. For VMAT plan, the surface dose reduced at most

represents an important topic due to the higher life expectancy after

points and the reductions were between 13% and 31%, while the

the treatments as a consequence of the high healing rate, increasing

dose slightly increased 2% at point 3. The surface dose at point 3

cancer incidence in the general population, and the increase in

decreased ﬁrst during the beam delivery because the bolus was

peripheral dose from new radiotherapy techniques.34 Literature

placed on the incident side of the beam and out of the ﬁeld when

demonstrates low radiation dose can induce severe side effects: it

the gantry faced the anterior part of the phantom, but the surface

has been reported that atomic bomb survivors in the dose range

dose also increased because point 3 was located on the exit side of

from 5 to 100 mSv show a signiﬁcantly increased incidence of solid

the beam when the gantry rotated to face the lateral and posterior

cancer compared with the population who were exposed to less

part of the phantom. For the other points, the amount of dose

than 5 mSv,35 a signiﬁcant risk for acute leukemia was seen in young
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T A B L E 3 Measured surface dose (mean  SD of the mean) when 1-cm Superﬂab bolus was placed on the contralateral breast of an
anthropomorphic phantom and PMRT plans (VMAT, 4-ﬁeld IMRT and Tomotherapy) were delivered to the phantom. Doses, expressed in cGy,
correspond to a total prescription dose of 50 Gy. The measurement locations are shown in Fig. 2.
VMAT
Point

No of bolus

With bolus

1

323.1  2.7

254.3  2.2

2

127.3  2.0

88.3  1.7

4-ﬁeld IMRT
Difference (%)

No of bolus

With bolus

21

764.4  7.1

1282.3  22.3

31

191.8  3.0

78.5  1.1

Tomotherapy
Difference (%)
68
59

No of bolus

With bolus

Difference (%)

517.1  7.2

532.2  18.8

3

208.0  2.2

209.4  3.0

1

3

62.4  2.7

63.4  0.7

2

70.9  2.4

31.5  0.3

56

267.6  8.3

271.9  3.8

2

4

173.1  4.3

140.6  3.6

19

216.3  6.3

81.8  1.7

62

316.0  3.4

320.5  3.0

1

5

184.1  2.5

160.1  6.8

13

77.0  0.9

36.0  1.4

53

201.5  2.2

212.7  2.3

6

individuals who were exposed to fallout from nuclear test site and

The surface dose reduction was 13–31% for the VMAT plan and

received bone-marrow doses from 6 to 30 mSv,36 thyroid and breast

53–62% for the 4-ﬁeld IMRT plan, but the bolus effect was not

cancers occurred in children when radiation doses were as low as

obvious for the Tomotherapy plan. In conclusion, using a bolus in

100 mGy,37 and lung cancers happened for doses of 500 mGy in

out-of-ﬁeld area and on the incident side of the beam can signiﬁ-

38

The method presented in this study to reduce peripheral

cantly reduce surface and shallow depth doses, but the absolute

dose is a simple and important tool that could be used in clinical

amount of dose change will be determined by the beam angles and

routine to reduce patients’ risk of developing radiation-induced side

how the radiotherapy plan was optimized. Although we only vali-

effects and increase patients’ safety.

dated this dose reduction strategy for advanced PMRT treatments

adults.

One limitation of this study is that we only evaluated this bolus
effect for Elekta linac because this is the only type of linac in our

using one type of linac, it should be applicable to any external beam
radiotherapy.

clinic, while the other types like Varian machines may generate different results and investigation of this dose reduction strategy using
other types of linacs will broaden the generality of our ﬁndings.
However, the methodology of this study is generally applicable and
clinics that have different types of machines could evaluate and validate this bolus effect easily using our approach. The other possible
limitation is that we only validated this dose reduction strategy for
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or other cancer sites was not included. Tangential planning was
already evaluated by Jamal and Das31 for whole breast irradiation
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4 | CONCLUSIONS
We evaluated surface and shallow depth dose reductions under various conditions by placing the Superﬂab boluses of various thicknesses on a solid water phantom. The skin dose reduction caused
by the bolus was achieved in out-of-ﬁeld area and on the incident
side of the beam, and the bolus effect increased with bolus thickness. The dose reduction caused by the bolus was more signiﬁcant
at closer distances from the beam. Most of the dose reduction
occurred in the ﬁrst 2-cm depth and stopped at 4-cm depth. We
also evaluated this dose reduction strategy in clinically realistic situations by placing a 1-cm Superﬂab bolus on the contralateral breast
of an anthropomorphic phantom and delivered PMRT plans to it.
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